SCHEMBL29208697

SCHEMBL29208697

O=C(O)C1=CCN(c2ncc(C(F)(F)F)cn2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 6/20 0.43
PPARG P37231 1/20 0.41
PPARD Q03181 1/20 0.41
PPARA Q07869 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
RIPK1 Q13546 2/20 0.40
RORC P51449 1/20 0.40
TIPARP Q7Z3E1 2/20 0.39
CHRM2 P08172 2/20 0.39
CHRM1 P11229 2/20 0.39
ALDH1A1 P00352 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 1/20 0.37
PARP1 P09874 1/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ACACB O00763 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29208735 0.88 TIPARP (0.44) TRPV1PPARGPPARDPPARARIPK1
SCHEMBL21868477 0.84 RIPK1 (0.52) TRPV1RIPK1RORCKDM4EPARP1
SCHEMBL29208728 0.83 MAPT (0.53) ALDH1A1SMN1; SMN2KDM4EMEN1MAPT
SCHEMBL30776184 0.83 MAPT (0.53) ALDH1A1SMN1; SMN2KDM4EMEN1MAPT
SCHEMBL29208793 0.81 TRPV1 (0.40) TRPV1RIPK1RORCTIPARPCHRM1
SCHEMBL26124820 0.80 PPARG (0.41) TRPV1PPARGPPARDPPARANPC1
SCHEMBL26127908 0.80 PPARG (0.39) TRPV1PPARGPPARDPPARANPC1
SCHEMBL3815501 0.79 TRPV1 (0.54) TRPV1RORCALDH1A1KDM4EMAPT
SCHEMBL29208849 0.79 TRPV1 (0.39) TRPV1RIPK1SMN1; SMN2KDM4EKMT2A
SCHEMBL29208763 0.79 RIPK1 (0.42) TRPV1RIPK1CHRM2CHRM1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117777099-A PARP7 inhibitors and uses thereof 诺沃斯达药业(上海)有限公司 2024-03-29 CN disclosed